75849-11-5

Basic information

• Product Name: 1-(benzyloxy)-3-(3-bromopropyl)benzene
• Synonyms: 1-(benzyloxy)-3-(3-bromopropyl)benzene
• CAS NO: 75849-11-5
• Molecular Weight: 305.214
• Mol File: 75849-11-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(benzyloxy)-3-(3-bromopropyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(benzyloxy)-3-(3-bromopropyl)benzene(75849-11-5)
• EPA Substance Registry System: 1-(benzyloxy)-3-(3-bromopropyl)benzene(75849-11-5)

Safety Data

• Hazardous Substances Data: 75849-11-5(Hazardous Substances Data)

Upstream product

• 121484-76-2 3-(3-benzyloxy-phenyl)-propionyl chloride 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 14755-02-3 3-hydroxycinnamic acid 
• 75849-10-4 ethyl 3-<3-(benzyloxy)phenyl>propanoate 
• 57668-35-6 3-[3-(Benzyloxy)phenyl]-1-propanol 

Downstream Products

• 1380328-05-1 (R)-2-((2R,3R)-7-(3-(benzyloxy)phenyl)-3-((4-methoxybenzyl)oxy)heptan-2-yl)oxirane 
• 1380328-08-4 (R)-7-(2-(((2R,4S,5R,6R)-6-(4-(3-(benzyloxy)phenyl)butyl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)methyl)-1,3-dithian-2-yl)-7-methyloct-1-en-4-ol 
• 1160697-43-7 ethyl 5-(3-(benzyloxy)phenyl)pentanoate 
• 1380327-88-7 (1R,3R,4R,5S,9R,13R)-9-(hydroxymethyl)-3-(4-(3-hydroxyphenyl)butyl)-4,16,16-trimethyl-2,6,10,17-tetraoxatricyclo[11.3.1.1^1,5]octadecane-7,11-dione 
• 289034-17-9 C₁₈H₂₀O₂ 
• 1380328-03-9 (3S,4R)-8-(3-(benzyloxy)phenyl)-3-methyloct-1-en-4-ol 
• 1395894-22-0 C₂₃H₃₀O₂ 
• 1373922-68-9 C₂₀H₂₄O₂ 

Relevant articles and documents

Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug

10-Methyl-aplog-1 (1), a simplified analog of tumor-promoting aplysiatoxin, is a potential lead for cancer therapy that exhibits marked and selective growth inhibitory effects against several human cancer cell lines and negligible tumor-promoting activity in vivo. However, more detailed evaluations of its toxicity and anticancer activity in vivo are hampered by supply problems associated with a non-optimal synthetic method. We here addressed this issue through a more practical and reliable synthetic method that afforded several hundred milligrams of 1 with high purity (>98%) in 23 steps from commercially available m-hydroxycinnamic acid with an overall yield of 1.1%. The utilization of two key reactions, substrate-controlled epoxidation and the oxidative cleavage of alkene with a free hydroxyl group, successfully reduced the existing five synthetic steps and markedly improved the handling of large amounts of intermediates. We also demonstrated for the first time that such an analog was synthetically accessible in reliable quantities and also that this large supply could advance in vivo trials for the treatment of cancer.